Long-term outcomes in Waldenström macroglobulinemia (WM) patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback